Phase I study of ABM-1310 as monotherapy and in combination with cobimetinib for BRAF-mutated advanced solid tumors: safety, efficacy, and dose expansion

Puntos clave

• ABM-1310 demonstrates favorable safety and encouraging intracranial activity for patients with BRAF-mutated tumors.
• The study shows that intracranial activity was particularly notable in patients with prior BRAF inhibitor exposure.
• Assessment involved evaluating safety and efficacy, focusing on advanced solid tumors driven by BRAF mutations.
• These findings support the continued exploration of ABM-1310 in treating CNS tumors and BRAF-inhibitor-experienced patient populations.